Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Epigenetic Regulation

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.

Epigenetic Regulation

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The role of <i>trans</i>-acting factors in the pathogenesis of common psychiatric disorders.

Epigenetics·2026

Same author

Vafidemstat: a lysine-specific demethylase 1A inhibitor that shows promise for treating neuropsychiatric disorders.

Epigenetics reports·2025

Same author

Inhibition of Contractility of Isolated Caprine Detrusor by the Rho Kinase Inhibitor Fasudil and Reversal by the Guanylyl Cyclase Inhibitor ODQ.

Current therapeutic research, clinical and experimental·2025

Same author

Histone monoaminylation is a novel epigenetic mechanism in psychiatric disorders.

Frontiers in molecular neuroscience·2025

Same author

The Role of Epigenetics in the Pathogenesis and Potential Treatment of Obsessive-compulsive Disorder.

Current neuropharmacology·2025

Same author

Editorial: Epigenetics and neurodevelopment in psychiatry.

Frontiers in genetics·2024

Search research articles

Related Experiment Video

Updated: Mar 26, 2026

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

Epigenetic Drugs for Multiple Sclerosis.

Jacob Peedicayil¹

¹Department of Pharmacology and Clinical Pharmacology Christian Medical College Vellore India. jpeedi@cmcvellore.ac.in.

Current Neuropharmacology

|January 28, 2016

Summary

Epigenetic drugs, including DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi), show promise for treating multiple sclerosis (MS). These therapies target gene expression abnormalities and could enhance clinical management for MS patients.

More Related Videos

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Related Experiment Videos

Last Updated: Mar 26, 2026

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Area of Science:

Neuroimmunology
Pharmacology
Epigenetics

Background:

Multiple sclerosis (MS) development is increasingly linked to epigenetic gene expression abnormalities.
Epigenetics has spurred the development of novel therapeutic agents, known as epigenetic drugs.

Purpose of the Study:

To discuss the potential of epigenetic drugs, specifically DNMTi and HDACi, in treating MS.
To review preclinical findings for these drug classes in MS models.

Main Methods:

Focus on drugs inhibiting DNA methyltransferase (DNMTi).
Focus on drugs inhibiting histone deacetylase (HDACi).
Review of preclinical drug trials for MS treatment.

Main Results:

Preclinical trials of DNMTi and HDACi for MS demonstrate encouraging outcomes.
Epigenetic drugs represent a potential new avenue for MS therapy.

Conclusions:

Epigenetic drugs, particularly DNMTi and HDACi, hold significant therapeutic potential for multiple sclerosis.
These agents may offer improved clinical management strategies for individuals with MS.